文献速递乳腺癌

帕博利珠单抗单药一线治疗PD-L1阳性转移性三阴性乳腺癌:II期KEYNOTE-086研究B队列

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
PubMed 文献 · Ann Oncol · 2019-01-01

在II期KEYNOTE-086研究B队列中,评估帕博利珠单抗单药一线治疗PD-L1阳性转移性三阴性乳腺癌。84例患者中客观缓解率21.4%,疾病控制率23.8%,中位无进展生存期2.1个月,中位总生存期18.0个月。安全性可控,显示持久抗肿瘤活性。

要点

  • 帕博利珠单抗200 mg每3周静脉给药,最多2年,用于PD-L1阳性转移性三阴性乳腺癌一线治疗。
  • 84例患者客观缓解率21.4%(95% CI 13.9-31.4),疾病控制率23.8%(95% CI 15.9-34.0)。
  • 中位无进展生存期2.1个月(95% CI 2.0-2.2),中位总生存期18.0个月(95% CI 12.9-23.0)。

核心结论

  • 帕博利珠单抗单药一线治疗PD-L1阳性转移性三阴性乳腺癌具有可控的安全性,并显示出持久的抗肿瘤活性。

研究设计与样本

  • II期KEYNOTE-086研究B队列,评估帕博利珠单抗单药一线治疗PD-L1阳性转移性三阴性乳腺癌。
  • 入组84例患者,均为女性,其中73例(86.9%)既往接受过(新)辅助治疗。
  • 患者接受帕博利珠单抗200 mg静脉给药,每3周一次,最多2年。
  • 主要终点为安全性,次要终点包括客观缓解率、疾病控制率、缓解持续时间、无进展生存期和总生存期。

主要发现

  • 53例(63.1%)患者发生治疗相关不良事件,其中8例(9.5%)为3级;无患者发生4级不良事件或死于治疗相关不良事件。
  • 4例完全缓解,14例部分缓解,客观缓解率为21.4%(95% CI 13.9-31.4)。
  • 13例疾病稳定患者中2例稳定持续≥24周,疾病控制率为23.8%(95% CI 15.9-34.0)。
  • 数据截止时,18例缓解者中8例(44.4%)缓解持续,中位缓解持续时间为10.4个月(范围4.2至19.2+)。
  • 中位无进展生存期为2.1个月(95% CI 2.0-2.2),中位总生存期为18.0个月(95% CI 12.9-23.0)。

关键数值与推荐

  • PD-L1联合阳性评分≥1为入组条件。
  • 客观缓解率21.4%(95% CI 13.9-31.4),疾病控制率23.8%(95% CI 15.9-34.0)。
  • 中位无进展生存期2.1个月(95% CI 2.0-2.2),中位总生存期18.0个月(95% CI 12.9-23.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new treatment options are needed. In cohort B of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as first-line therapy for patients with PD-L1-positive mTNBC. PATIENTS AND METHODS: Eligible patients had centrally confirmed mTNBC, no prior systemic anticancer therapy for metastatic disease, measurable disease at baseline per RECIST v1.1 by central review, no radiographic evidence of central nervous system metastases, and a tumor PD-L1 combined positive score ≥1. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. The primary end point was safety. Secondary end points included objective response rate, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), duration of response, progression-free survival and overall survival. RESULTS: All 84 patients enrolled were women, and 73 (86.9%) received prior (neo)adjuvant therapy. Fifty-three (63.1%) patients had treatment-related adverse events (AEs), including 8 patients (9.5%) with grade 3 severity; no patients experienced grade 4 AEs or died because of treatment-related AEs. Four patients had a complete response and 14 had a partial response, for an objective response rate of 21.4% (95% CI 13.9-31.4). Of the 13 patients with stable disease, 2 had stable disease lasting ≥24 weeks, for a disease control rate of 23.8% (95% CI 15.9-34.0). At data cut-off, 8 of 18 (44.4%) responses were ongoing, and median duration of response was 10.4 months (range 4.2 to 19.2+). Median progression-free survival was 2.1 months (95% CI 2.0-2.2), and median overall survival was 18.0 months (95% CI 12.9-23.0). CONCLUSIONS: Pembrolizumab monotherapy had a manageable safety profile and showed durable antitumor activity as first-line therapy for patients with PD-L1-positive mTNBC. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02447003.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019. PMID: 30475947. doi:10.1093/annonc/mdy518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。